8-Year HERA Results: 2 Years of Trastuzumab Therapy Does Not Improve Outcomes vs 1 Year Therapy Following Adjuvant Chemotherapy in HER2-Positive Early Breast Cancer

Capsule Summary - These findings, in tandem with the durable benefits seen with 1 year of trastuzumab compared with observation, confirm that adjuvant trastuzumab for 1 year remains standard of care for patients with HER2-positive early breast cancer.
Source: Clinical Care Options Oncology - Breast Cancer - Category: Cancer & Oncology Source Type: research